Overview

* Inhibrx Q3 net loss widens, missing analyst expectations for EPS and net income

* R&D expenses decreased due to reduced process development and headcount

* Cash and cash equivalents decreased to $153.1 mln from $186.6 mln in Q2 2025

Outlook

* Inhibrx plans to submit a biologics license application in Q2 2026

* Interim data shows high response rates in colorectal cancer and Ewing sarcoma

Result Drivers

* R&D EXPENSES - Decrease in R&D expenses due to reduced process development and manufacturing activities

* CLINICAL TRIAL RESULTS - Positive topline results from ozekibart trial in chondrosarcoma, meeting primary endpoint

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 EPS Miss -$2.28 -$1.72

(1

Analyst)

Q3 Net Miss -$35.26 -$26.61

Income mln mln (1

Analyst)

Q3 Miss -$33.81 -$28.98

Operatin mln mln (1

g Income Analyst)

Q3 $33.81

Operatin mln

g

Expenses

Analyst Coverage

* The one available analyst rating on the shares is "hold"

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)